智通财经APP获悉，同源康医药-B(02410)涨超5%，截至发稿，涨4.92%，报11.34港元，成交额2758.77万港元。
消息面上，3月4日，同源康医药-B发布公告，本公司董事会欣然宣布，460.8万股非上市股份已于2026年3月4日完成转换为H股，该等经转换H股将于2026年3月5日上午九时正开始于联交所上市。
近期，同源康医药-B宣布，其自主研发的针对非小细胞肺癌(NSCLC)脑转移的甲磺酸艾多替尼片(TY-9591)新药上市申请(NDA)已获得中国国家药品监督管理局(NMPA)药品审评中心(CDE)正式受理。这是首个针对肺癌脑转移的新一代EGFR-TKI抑制剂。此次提交的NDA是基于一项在中国开展的多中心、随机、开放标签、阳性对照的关键注册性临床研究(ESAONA)(NCT05948813)结果。此项研究的结果将于近期发布于国际学术大会或学术期刊。
更多港股重磅资讯，下载智通财经app
更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.